July 3, 2025 Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease Read about Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
May 16, 2025 Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025 Read about Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025
April 29, 2025 Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development Read about Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development
April 24, 2025 Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025 Read about Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025
April 8, 2025 Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025 Read about Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025
March 25, 2025 Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024 Read about Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024
March 14, 2025 PUBLICATION ALERT: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery Read about PUBLICATION ALERT: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery
March 10, 2025 PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection Read about PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
March 6, 2025 PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT Read about PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT
February 19, 2025 PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA Read about PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA
February 11, 2025 Acuitas Therapeutics named one of BC’s Top Employers of 2025 Read about Acuitas Therapeutics named one of BC’s Top Employers of 2025
February 6, 2025 PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays Read about PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays